[Our experience with infliximab in reclacitrant cases of psoriasis].
Present report is focused in our personal experience with the anti TNF-alpha infliximab. There is a short, four case series, but they are a very representative sample of the clinical conditions that we can solve with infliximab.
Pereiro
M
M
Departamento de Dermatología, Complejo Hospitalario Universitario, Facultad de Medicina, Santiago de Compostela, La Coruña, España. manuelpe@usc.es
González-Vilas
D
D
Sánchez-Aguilar
D
D
Toribio
J
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab